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Deep vein thrombosis (DVT) is a clinical 
challenge encountered by clinicians of all 
specialties. The major complication to date is 
thrombus embolization into the lung which can 
be fatal.1 The mainstay of DVT therapy is an 
anticoagulant to prevent the thrombus development 
and recurrence. However, anticoagulant has no 
direct thrombolysis effect and recanalization of 
DVT largely depends on the effectiveness of the 
endogenous fi brinolytic system.2 Many agents are 
developed to improve the outcome and prevent 
a post thrombotic syndrome (PTS). The aim of 
this review is to give explanation on the use of 
anticoagulant, especially vitamin K antagonist, 
warfarin and thrombolytic therapy in DVT.
The Management of DVT
The therapy of choice in DVT consist of 
anticoagulant, vena cava fi lter, thrombolytic agents 
and surgical thrombectomy.
 Anticoagulant
Anticoagulant therapy in DVT consist of 
the use of heparin and oral anticoagulant. Due 
to an unacceptable rate of recurrent venous 
thromboembolic complication with the use of sole 
oral anticoagulation, heparin are used for 5-10 days 
in concomitant with oral anticoagulants.3 Warfarin, 
an oral anticoagulant, needs unfractionated 
heparin or low-molecular-weight heparin during the 
fi rst few days of warfarin therapy as a “bridge”, as 
warfarin therapy may take up to 5 days to achieve 
its antithrombotic effect. This is due to the long half-
life of circulating prothrombin which is 60 days.4
Warfarin is still an important drug with many 
clinical indication. In the most clinical cases, the 
rate of thromboembolism is reduced by the use of 
this vitamin K antagonist. Unfortunately, warfarin 
interacts with some food and many medicines. The 
interaction can affects an INR level, an indicator 
of blood anticoagulation state. Foods that contain 
high level of vitamin K may affect warfarin activity. 
Some medicines that can increase or decrease 
INR level are listed in table 1. 
Table 1. Medicines that interact with warfarin
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For the fi rst fi ve to ten days, warfarin initiation 
consists of the use of unfractionated heparin 
(UFH), low molecular weight heparin (LMWH) 
or pentasaccharide (fondaparinux) concurrently 
with warfarin. Unfractionated heparin could be 
given with fixed dose 1250 IU/hour or using 
body weight, 80 IU/kg body weight intravenous 
bolus and maintain with 18 IU/kg body weight 
per hour. Alternative use of intravenous UFH is 
subcutaneous UFH with fi xed dose 333 IU/kg body 
weight dan 250 IU/kg body weight per day. Both 
modalities, either intravenously or subcutaneously, 
has already been tested in 972 patients and 
subcutaneous UFH has comparable efectivity and 
safety as compare with UFH intravenous.7
The American College of Chest Physician 
(ACCP) recommends warfarin therapy in the fi rst 
day dan titrated to achieve target INR >2.8 The 
length of anticoagulant therapy is based on the 
clinical disease. Figure 1 shows anticoagulant 
duration for DVT. 
Hemorrhage is still the major concern of oral 
anticoagulant therapy and warfarin poses this risk.5 
In many clinical studies, treatment with warfarin 
increases the risk of major bleeding by 0.3-0.5% 
per year and the risk of intracranial hemorrhage 
approxiamately 0.2% per year compared to controls. 
Risk of major bleeding in warfarin use can be lowered 
with strict monitoring. There is a need to outweigh 
the risk of bleeding and the benefi t of the therapy. 
Phrotrombin time (PT) or International Normalized 
Ratio (INR) are used to monitor warfarin level. The 
target of INR in patient using warfarin is 2-3 and this 
value causes less risk of bleeding as compare to the 
target of INR  > 3.6  Table 2 show the frequency of 
monitoring in warfarin initiation. 
 
Figure 1. Protocol therapy of deep vein thrombosis 9
Table 2.Monitoring of INR with patients10
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With the use of optimal anticoagulant, repeated 
venography in six month after DVT therapy in 
femoral vein and other distal veins shows complete 
lysis in 38% patients, partial resolution in 54% 
and propagation in 7%.11 Moreover, in 1 year after 
therapy, vein abnormalities using compression 
ultrasonography were found in 50% patients.11 
Despite anticoagulation, infl ammatory reaction may 
develop within 7-10 days after acute onset of disease. 
Infi ltration of fi broblast and neovascularization will 
damage the venous valve and cause post thrombotic 
syndrome (PTS). Post thrombotic syndrome is 
caused by chronic venous hypertension secondary 
to venous refl ux, venous obstruction and valvular 
dysfunction. It is estimated that 80% patients with 
DVT may go on to develop symptoms of PTS while 
4-15% progress to leg ulceration.12 It is believed 
that rapid recanalization in DVT could prevent the 
development of PTS.2 However, studied showed 
that anticoagulant has no direct thrombolysis effect 
and recanalization on DVT largely depends on the 
effectiveness of the endogenous fi brinolytic system.2 
Researchers began to look for agents that could do 
rapid recanalization in DVT to prevent complication 
and reccurence. 
Thrombolytic Agents
Randomized trials have consistently 
shown that thrombolytic therapy rapidly resolves 
thromboembolic obstruction and exerts benefi cial 
effects on haemodynamic parameters. Regimens 
that are approved are streptokinase, urokinase 
and rtPA. Approxiamately 94% of patients can be 
classifi ed based on clinical and echocardiographic 
improvement within the first 36 hours. The 
greatest benefi t is observed when treatment is 
initiated within 48 hours of symptom onset, but 
thrombolysis can still be useful in patients who 
had symptoms for 6-14 days.13
Thrombolytic therapy poses signifi cant risk 
of bleeding with overall bleeding rate is 13% and 
1.8% major bleeding and intracranial hemorrhage.13 
However, even with the increase risk of bleeding, there 
come the greater benefi t of rapid recanalization. The 
earliest trial in thrombolytic therapy was conducted by 
Robertson et al. in 1968 that compare streptokinase 
vs. heparin in 16 DVT subjects. In this trial, there 
were signifi cant lysis of thrombus in streptokinase 
group (63%) compared to in heparin group (12%). 
Risk of bleeding also increased in streptokinase 
group (25%) compared to in heparin group (12%). In 
Cochrane Analysis consisted of 12 studies and 701 
subjects overall, relative risks for major bleeding is 
1.7 (95% CI, 1.04 to 2.9; 668 subjects in 10 studies) 
and signifi cant intracranial hemorrhage 1.7 (95% CI, 
0.2 to 14; 701 subjects in 5 studies) in thrombolytic 
group.10 However, looking at the balance between 
benefi t of rapid recanalization and risk of bleeding, 
in some patients the benefi t of rapid recanalization 
outweigh the risk of bleeding.
Catheter directed thrombolysis (CDT) is a 
method to introduce plasminogen activator agents 
directly into the thrombus. This method is more 
efficient because it causes local thrombolysis 
and improves venous patency, and at the same 
time reduces the risk in systemically used 
thrombolysis.12 In the study comparing thrombolytic 
given systemically and CDT, valvular competence 
is preserved in 44% of patients using CDT 
vs. 13% patients using systemic thrombolysis 
(p=0.049).14 Most CDT associated complications 
are local and systemic hemorrhage. CDT related 
bleeding is 5-11% and higher rates are associated 
with prolonged infusion time and high doses of 
thrombolytic agents used.12
American College of Physician suggests 
the use of CDT in selected patients whose life 
expectancy are > 1 year, good functional status, 
extensive illiofemoral thrombosis and presenting 
soon after the onset of symptoms (<14 days) (level 
2B evidence). This proposition is based on small 
RCTs, registry data, institusional series and variety 
of expert opinions.15
Conclusion
Anticoagulant and thrombolytic are two of 
the modalities use in the management of DVT. 
Anticoagulant is the mainstay therapy of DVT, but the 
risk of valve incompetency due to slowly resolving 
thrombus is high. This could lead to reccurence of 
DVT and PTS. Thrombolytic is an agent that conveys 
rapid recanalization to prevent complication of 
DVT. However the use of thrombolytic agent poses 
greater risk of bleeding and since the evidence of 
thrombolysis is based on small RCTs, this therapy 
is only reserved for selected patients. 
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